- Home
- YHGJ vs VYNE Comparison
YHGJ vs VYNE Comparison
Compare YHGJ & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | VYNE |
|---|---|---|
| Founded | 1975 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 12.5M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | YHGJ | VYNE |
|---|---|---|
| Price | $3.98 | $0.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 15.0M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,377,000.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.41 | ★ 6.29 |
| 52 Week Low | $3.37 | $0.28 |
| 52 Week High | $12.70 | $4.30 |
Technical Indicators
Market Signals| Indicator | YHGJ | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 63.92 |
| Support Level | $3.53 | $0.55 |
| Resistance Level | $3.99 | $0.58 |
| Average True Range (ATR) | 0.28 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 54.78 | 22.87 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.